Rebekah Sizemore’s son Naithan recently lost his Earthly life to DIPG, Diffuse Intrinsic Pontine Glioma, which is one of the deadliest pediatric cancers with virtually no survivors. In tribute to Naithan in his birthday month, she is researching statistics for pediatric cancer, and is sharing her findings with her subscribers onand is allowing us at Jack’s Angels to share this information as well.
Her contribution is vitally important; we as a society cannot hear of these statistics too many times, until changes are made by our representatives in legislation. Awareness is crucial to change. Thank you for supporting Rebekah and Jack’s Angels in your willingness to be aware of these facts that are daily companions, if not hourly, to many of us:
The numbers are abhorrent
By Rebekah Sizemore 3.4.2014
- Why Research is Needed
In developed countries like the United States , Canada , Western European countries, Japan and Australia , cancer remains the most common disease killer of children. In developing countries, more than one in two children diagnosed with cancer are likely to die.2 This is because cancer is detected late and only a small proportion of children have access to the comprehensive cancer treatments currently available in the developed world. Childhood cancer is becoming a more important health issue for these countries and the world community as infectious diseases and diarrhea become increasingly eliminated.
In the U.S. and other developed countries, the 1970s-80s brought the advent of chemotherapy ‘cocktails’ applied to childhood cancer, where toxic compounds that preferentially killed the tumor cells kept many children from death. In spite of tens of millions of public dollars being allocated towards clinical trial research in the U.S. in the past decade, there has been no change in survivorship of childhood cancer in the past 10 years.2 From 1975 to 1998 the annual death rate from childhood cancer in the U.S. declined at a rate of 2.7% per year. Despite very aggressive therapies that approach the limits of tolerability for the child, the overall survival rate for childhood cancer has remained unchanged since 1998. One in four children who are diagnosed with cancer in the U.S. will die within five years of their diagnosis, and 30% of those that do survive have severe side effects, including cognitive deficits, kidney failure, heart failure, and secondary cancers caused from the traditional toxic treatments. Because of the high level of toxicity associated with many current treatments and the plateau in survivorship rates, future success is dependent upon the development of new therapeutic approaches.
Newly emerging adult cancer therapy is focused on drugs that kill only the cancer, and are not toxic to the normal cells of the patient. They accomplish this by using molecular genetic approaches to identify the ‘Achilles heel’ of each specific tumor type, then attacking this weak spot in a highly specific manner. This “targeted therapeutics” has had great success in a number of adult cancers. Unfortunately, pediatric cancers are so different from adult cancers that targeted therapeutics must be developed specifically for pediatric cancer. It is imperative that research initiatives take place for childhood cancer that utilizes and integrates the latest molecular techniques for pediatric cancers, including: comparative genomic hybridization, large-scale re-sequencing of key oncogenes, proteomic profiling (particularly signaling pathways; phosphoproteomic profiling), and mRNA profiling.
The identification of such therapeutic targets is essential to the future progress in identifying more effective therapies for children with cancer. Specifically, “target identification” is the first step in the high throughput drug screening pipeline (HTS), enabling subsequent assay development, high throughput screening, drug development, and pre-clinical and clinical studies. Through the development of molecularly targeted drugs for children with cancer, children world-wide could benefit from cancer therapies that would require minimal supportive care in contrast to today’s toxic therapy. Children would benefit from additional drugs leading to a greater number of cures, and cures that would not be associated with life-long severe medical late-effects currently caused by standard cancer treatments.
1 International Agency for Research on Cancer, Globocan, 2002
2 Global Action Against Cancer ( Geneva : UICC/WHO, updated edition 2005)
3 Ries, L. A. G., Eisner, M. P., Kosary, C. L., Hankey, B. F., Miller, B. A., Clegg, L., Mariotto, A., Feuer, E. J., and Edwards, B. K. SEER Cancer Statistics Review, 1975-2002. 2005. National Cancer Institute. Bethesda , MD.